Back to search

Article

Serum Proteomics of Ribociclib-Mediated Cardiovascular Toxicity: An Exploratory Case-Control Study

2025-02-26

Abstract excerpt

Cyclin-dependent kinase 4/6 inhibitors have transformed hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer therapeutics. Ribociclib has been associated with survival gain, yet its potential cardiovascular toxicities (CVTs) remain an area of uncertainty. Our single-center study prospectively recruited adult patients in order to assess treatment-related...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
11457a18-c84c-57ec-a708-242f65d86591
DOI
10.22541/au.174055876.60803084/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Serum Proteomics of Ribociclib-Mediated Cardiovascular Toxicity: An Exploratory Case-Control StudyDOI 10.22541/au.174055876.60803084/v1
High neutrophils and triglycerides lead to critical illness in COVID-19 and reveal CDK6 inhibitors as potential treatmentSemantic proximity
Cardiotoxicity Associated with Targeted Therapies in Lung Cancer: A Retrospective Cohort Study of 2,427 Patients with FAERS Pharmacovigilance ValidationSemantic proximity
Kinome profiling allows examination and prediction of kinase inhibitor cardiotoxicitySemantic proximity
CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological ConditionsSemantic proximity
Cardiovascular Risks with Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors and Monoclonal Antibody Therapy.Semantic proximity
Adverse Event Profiles of CDK4/6 inhibitors: A pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) databaseSemantic proximity
Genetic factors in the pathogenesis of cardio-oncology.Semantic proximity
Critically ill COVID-19 status associated trait genetics reveals CDK6 inhibitors as potential treatmentSemantic proximity
A chromosomal translocation in cyclin D1–negative/cyclin D2–positive mantle cell lymphoma fuses the CCND2 gene to the IGK locusSemantic proximity
Three-year cardiovascular and non-cardiovascular adverse events in patients with chronic lymphocytic leukemia or small cell lymphocytic lymphoma treated with Bruton tyrosine kinase inhibitors acalabrutinib or ibrutinib: a real-world analysisSemantic proximity
Circulating microRNAs and therapy-associated cardiac events in HER2-positive breast cancer patients: an exploratory analysis from NeoALTTOSemantic proximity
The future role of pharmacogenomics in anticancer agent-induced cardiovascular toxicity.Semantic proximity
Select a neighboring publication to make it the new centre.